Emily Chan - Concepedia

Author

Emily Chan

Vanderbilt University Medical Center ORCID

Also Known As

Chan E, Chan, Emily, Chan, Eunice YS, E Chan, E W E Chan, E. Chan, Emily Chan, Emily W. Chan, Ivanova, Anastasia, M M Akhter Rahman

211

Publications

11.1K

Citations

H-Index

Concepts

All Affiliations

Vanderbilt University Medical Center Vanderbilt University The University of Texas MD Anderson Cancer Center Vanderbilt-Ingram Cancer Center Memorial Sloan Kettering Cancer Center

About

Emily Chan is an author at Vanderbilt University Medical Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	31	3K
2	Health Sciences	5	5	571
3	Cell Biology	4	4	386
4	Public Health	2	2	53
5	Social Sciences	1	1	77

Emily Chan

Publications

9.4K

Citations

H-Index

Page 1

	Year	Citations
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations David M. Hyman, Igor Puzanov, Vivek Subbiah, New England Journal of Medicine	2015	1.7K
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose Christine H. Chung, Beloo Mirakhur, Emily Chan, New England Journal of Medicine	2008	1.5K
Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer Scott Kopetz, Jayesh Desai, Emily Chan, Journal of Clinical Oncology	2015	678
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial Padmanee Sharma, Margaret K. Callahan, Petri Bono, The Lancet Oncology UrologyGenitourinary CancerMedicineCheckmate 032Immune Checkpoint Inhibitor	2016	676
Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation Ryan Raisner, Samir Kharbanda, Lingyan Jin, Cell Reports	2018	398
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study Van K. Morris, Mohamed E. Salem, Halla Nimeiri, The Lancet Oncology MedicineImmune Checkpoint InhibitorSurgeryCancer TreatmentOncology	2017	383
A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial Julio García‐Aguilar, Qian Shi, Charles R. Thomas, Annals of Surgical Oncology Surgical OncologyRadiation TherapyT2n0 Rectal CancerMedicineGastrointestinal Oncology	2011	299
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal Patrick A. Ott, Sarina A. Piha‐Paul, Pamela N. Münster, Annals of Oncology	2017	250
Colon Cancer, Version 3.2014 Al B. Benson, Alan P. Venook, Tanios Bekaii‐Saab, Journal of the National Comprehensive Cancer Network Surgical OncologyPrior TherapyGastrointestinal OncologyColorectal SurgeryMedicine	2014	221
Activation of p38 Mitogen-Activated Protein Kinase Is Required for Osteoblast Differentiation Yuanyu Hu, Emily Chan, Sherry X. Wang, Endocrinology SclerostinCell DeathP38 MapkCellular PhysiologyOsteoporosis	2003	197

Page 1